Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin

Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin

Lipoprotein(a) [Lp(a)] is a cardiovascular risk factor, and there is considerable interest in developing Lp(a)-lowering therapeutics for cardiovascular prevention. Current commercial Lp(a) assays measure total apolipoprotein(a) [apo(a)] and may be insufficient to accurately measure Lp(a) concentrati...

Full description

Saved in:
Bibliographic Details
Main Authors: Craig A. Swearingen, John H. Sloan, Grace M. Rhodes, Robert W. Siegel, Nico Bivi, Yuewei Qian, Robert J. Konrad, Michael Boffa, Marlys Koschinsky, John Krege, Giacomo Ruotolo, Stephen J. Nicholls, Laura F. Michael, Yi Wen
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Journal of Lipid Research
Subjects:
Lipoprotein (a)
antibodies
lipoprotein (a) metabolism
clinical trials
drug therapy
cardiovascular disease
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227524002281
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S0022227524002281

Similar Items